---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-21-004750"
form_type: "8-K"
ticker: "ACET"
cik: "0001720580"
company_name: "Adicet Bio, Inc."
filed_at: "2021-11-18T23:59:59+00:00"
generated_at: "2026-06-28T07:03:07.776953+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Adicet Bio appoints Dr. Michael Kauffman to board of directors

## Summary
- Appointed Michael Kauffman, M.D., Ph.D. to Board, effective Nov 17, 2021.
- Dr. Kauffman is independent and will serve on the Nominating and Corporate Governance Committee.
- Received option to purchase 37,000 shares at $9.39, vesting over 36 months.
- Over 20 years industry experience; co-founder and former CEO of Karyopharm; led Velcade development.
- Fills vacancy; board now includes three NCG committee members.

## SEC filing metadata
- accession: 0000950170-21-004750
- form_type: 8-K
- ticker: ACET
- cik: 0001720580
- company_name: Adicet Bio, Inc.
- filed_at: 2021-11-18T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1720580/000095017021004750/0000950170-21-004750-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1720580/000095017021004750/acet-20211117.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-21-004750
- JSON: https://secwatch.observer/filing/0000950170-21-004750.json
- Plain text: https://secwatch.observer/filing/0000950170-21-004750.txt

## Key facts
- Executive change
  Michael Kauffman was appointed as Director at Adicet Bio, Inc..
  - Action: appointed
  - Role: Director
  source text: On November 17, 2021, upon the recommendation of the Nominating and Corporate Governance Committee (the “NCG Committee”) of the board of directors (the “Board”) of Adicet Bio, Inc. (the “Company”), the Board appointed Michael Kauffman, M.D., Ph.D., to join the Board, effective as of November 17, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1720580/000095017021004750/0000950170-21-004750-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.